Skip to Content


Medically reviewed by Last updated on June 19, 2020.


(se LEE nee um)

Index Terms

  • Selenious Acid

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Selenicaps-200: 200 mcg [corn free, no artificial color(s), rye free, sugar free, wheat free, yeast free]

Capsule, Oral [preservative free]:

Se-100: 100 mcg [dye free, yeast free]

Liquid, Oral:

Aqueous Selenium: 95 mcg/drop (15 mL) [contains sodium benzoate]

Solution, Intravenous:

Generic: 40 mcg/mL (10 mL)

Solution, Intravenous [preservative free]:

Generic: 60 mcg/mL (10 mL)

Tablet, Oral:

Oceanic Selenium: 50 mcg, 200 mcg [animal products free, gelatin free, gluten free, kosher certified, lactose free, no artificial color(s), no artificial flavor(s), starch free, sugar free, yeast free]

Se Aspartate: 50 mcg

Se-Plus Protein: 200 mcg

Selenimin: 125 mcg [corn free, rye free, starch free, sugar free, wheat free]

Selenimin-200: 200 mcg [corn free, rye free, starch free, sugar free, wheat free, yeast free]

Generic: 50 mcg, 200 mcg

Tablet, Oral [preservative free]:

Generic: 50 mcg, 200 mcg

Tablet Extended Release, Oral [preservative free]:

Generic: 200 mcg

Brand Names: U.S.

  • Aqueous Selenium [OTC]
  • Oceanic Selenium [OTC]
  • Se Aspartate [OTC]
  • Se-100 [OTC]
  • Se-Plus Protein [OTC]
  • Selenicaps-200 [OTC]
  • Selenimin [OTC]
  • Selenimin-200 [OTC]

Pharmacologic Category

  • Trace Element, Parenteral


Part of glutathione peroxidase which protects cell components from oxidative damage due to peroxidases produced in cellular metabolism


Urine, feces, lungs, skin

Use: Labeled Indications

Trace metal supplement


Undiluted administration into peripheral vein

Dosing: Adult

Parenteral nutrition additive (Vanek 2012): IV: 60 to 100 mcg/day

Deficiency from prolonged parenteral nutrition: IV: 100 mcg/day

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Parenteral nutrition additive, maintenance requirement:

ASPEN recommendations:

Infants <10 kg: IV: 2 mcg/kg/day (ASPEN [Corkins 2015]; ASPEN [Mirtallo 2004]; ASPEN [Vanek 2012]; ASPEN [Vanek 2015]).

Infants and Children weighing 10 to 40 kg: IV: 1 to 2 mcg/kg/day (ASPEN [Corkins 2015]; ASPEN [Mirtallo 2004]); maximum daily dose: 100 mcg/day (ASPEN [Vanek 2012]; ASPEN [Vanek 2015]).

Children and Adolescents weighing >40 kg: IV: 2 mcg/kg/day; maximum daily dose: 100 mcg/day (ASPEN [Corkins 2015]; ASPEN [Vanek 2012]); ASPEN [Vanek 2015]).

ESPGHAN/ESPEN/ESPR/CSPEN recommendations (Demellöf 2018): Infants, Children, and Adolescents: IV: 2 to 3 mcg/kg/day; maximum daily dose: 100 mcg/day.


Oral: Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablets should be swallowed whole. Do not break, crush, or chew. IR tablet, capsule, oral solution, and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery. Bariatric vitamin supplementation is recommended on a lifelong basis after surgery; may consider integration of daily selenium regimen into the bariatric vitamin regimen.

Dietary Considerations

Dietary adequate intake (AI): Note: Breast milk, formula, and food should be the only sources of selenium for infants (NIH 2019).

1 to 6 months: 15 mcg/day.

7 to 12 months: 20 mcg/day.

Dietary recommended daily allowance (RDA) (IOM 2000):

1 to 3 years: 20 mcg/day.

4 to 8 years: 30 mcg/day.

9 to 13 years: 40 mcg/day.

≥14 years: 55 mcg/day.

Pregnancy: 60 mcg/day.

Lactation: 70 mcg/day.


Prior to use, store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Drug Interactions

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination

Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Consider therapy modification

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification

Dolutegravir: Selenium may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral selenium. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral selenium. Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.


Disease-related concerns:

• Gastrointestinal dysfunction: Use with caution in patients with GI impairment.

• Renal impairment: Use with caution in patients with renal impairment.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer’s labeling.

Monitoring Parameters

Plasma selenium concentration for patients receiving long-term PN (every 3 to 6 months; some patients (ie, HSCT) may require more frequent monitoring) (ASPEN Pediatric Nutrition Support Core Curriculum [Corkins 2010])

Pregnancy Considerations

Adverse events were seen with high doses in animal studies. Selenium is found in the placenta and cord blood. Teratogenic effects have not been observed with nontoxic doses in humans (IOM, 2000).

Patient Education

What is this drug used for?

• It is used to help growth and good health.

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Severe injection site redness, burning, pain, or swelling

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.